Madrigal Pharmaceuticals (MDGL) Total Current Liabilities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Total Current Liabilities data on file, last reported at $338.3 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 102.26% year-over-year to $338.3 million in Q1 2026; TTM through Mar 2026 was $338.3 million, a 102.26% increase from a year earlier, with the FY2025 full-year figure at $310.3 million, up 83.3% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $338.3 million, up from $310.3 million in the prior quarter.
• Over the last five years, Total Current Liabilities for MDGL reached as high as $391.4 million in Q3 2025 and fell as low as $76.6 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $163.6 million across 5 years, with a median of $118.5 million in 2023.
• Across the five-year window, Total Current Liabilities rose 0.75% in 2023 and jumped 120.08% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $115.9 million in 2022, then increased by 2.29% to $118.5 million in 2023, then jumped by 42.79% to $169.3 million in 2024, then soared by 83.3% to $310.3 million in 2025, then climbed by 9.01% to $338.3 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $338.3 million in Q1 2026, $310.3 million in Q4 2025, and $391.4 million in Q3 2025.